ST-1891 is under clinical development by Sention Therapeutics and currently in Phase II for Hypothyroidism. According to GlobalData, Phase II drugs for Hypothyroidism have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ST-1891’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ST-1891 is under development for the treatment of primary hypothyroidism. It is a thyroid hormone replacement therapy and is administered through oral route.
Sention Therapeutics overview
Sention Therapeutics is a biopharmaceutical company developing therapies for patients suffering from hypothyroidism. Sention Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of ST-1891’s drug-specific PTSR and LoA scores, buy the report here.